11-2002

Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis

Hong Ji  
*Harvard Medical School*

Allison Pettit  
*Harvard Institutes of Medicine*

Koichiro Ohmura  
*Harvard Medical School*

See next page for additional authors

Follow this and additional works at: https://escholarship.umassmed.edu/rheumatology_pubs

Part of the Immunopathology Commons, Musculoskeletal Diseases Commons, Rheumatology Commons, and the Skin and Connective Tissue Diseases Commons

Repository Citation

Ji, Hong; Pettit, Allison; Ohmura, Koichiro; Ortiz-Lopez, Adriana; Duchatelle, Veronique; Degott, Claude; Gravallese, Ellen M.; Mathis, Diane; and Benoist, Christophe, "Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis" (2002). *Rheumatology Publications and Presentations*. 35.  
https://escholarship.umassmed.edu/rheumatology_pubs/35

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Rheumatology Publications and Presentations by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis

Authors
Hong Ji, Allison Pettit, Koichiro Ohmura, Adriana Ortiz-Lopez, Veronique Duchatelle, Claude Degott, Ellen M. Gravallese, Diane Mathis, and Christophe Benoist

Comments
At the time of publication, Ellen Gravallese was not yet affiliated with the University of Massachusetts Medical School.

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.

Rights and Permissions
Publisher PDF posted as allowed by the publisher’s author rights policy at http://www.rupress.org/site/subscriptions/terms.xhtml.

This article is available at eScholarship@UMMS: https://escholarship.umassmed.edu/rheumatology_pubs/35
Critical Roles for Interleukin 1 and Tumor Necrosis Factor in Antibody-induced Arthritis

Hong Ji, Allison Pettit, Koichiro Ohmu ra, Adriana Ortiz-Lopez, Veronique Duchateau, Claude Degott, Ellen Grassalee, Diane Mathis, and Christophe Benoist

1 Section on Immunology and Immunogenetics, Joslin Diabetes Center and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215
2 Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale/Université Louis Pasteur, 67404 Strasbourg, France
3 Beth Israel Deaconess Medical Center and New England Baptist Bone and Joint Institute, Harvard Institutes of Medicine, Boston, MA 02215
4 Service d'Anatomie et de Cytopathologie, Hopital Beaujon, 92118 Clichy, France

Abstract

In spontaneous inflammatory arthritis of K/BxN T cell receptor transgenic mice, the effector phase of the disease is provoked by binding of immunoglobulins (Igs) to joint surfaces. Inflammatory cytokines are known to be involved in human inflammatory arthritis, in particular rheumatoid arthritis, although, overall, the pathogenetic mechanisms of the human affliction remain unclear. To explore the analogy between the K/BxN model and human patients, we assessed the role and relative importance of inflammatory cytokines in K/BxN joint inflammation by transferring arthritogenic serum into a panel of genetically deficient recipients. Interleukin (IL)-1 proved absolutely necessary. Tumor necrosis factor (TNF) was also required, although seemingly less critically than IL-1, because a proportion of TNF–deficient mice developed robust disease. There was no evidence for an important role for TNF for bone destruction. The variability in the requirement for TNF, reminiscent of that observed in treated rheumatoid arthritis patients, did not appear genetically programmed but related instead to subtle environmental changes.

Keywords: transgenic • cytokine • knockout • inflammatory • TNF

Introduction

Inflammatory arthritis, in particular rheumatoid arthritis, have been the focus of intense investigation, but their etiology and pathogenesis remain controversial. There is no consensus on what initiates rheumatoid arthritis (RA)*; i.e., whether it is primarily an autoimmune response, an inflammatory response to some persisting microbial invasion, or a combination of the two. There is also dispute over the leukocyte populations that are involved in the initiation of joint inflammation. The paradigm currently dominating the field portrays antigen-specific T cells in the joint as inducing the inflammatory cascade by triggering macrophages and synoviocytes (1, 2), but this scenario has been questioned for a lack of direct experimental demonstration of certain of its key points, and because of some discordant observations, such as the paucity of T cell-derived cytokines in inflamed joints (3). In contrast, a role for inflammatory cytokines like TNF and IL-1 is well established (4), with no evidence of any particular requirement for TNF for bone destruction. The variability in the requirement for TNF, reminiscent of that observed in treated rheumatoid arthritis patients, did not appear genetically programmed but related instead to subtle environmental changes.

*Abbreviations used in this paper: CIA, collagen-induced arthritis; GPI, glucose-6-phosphate isomerase; LT, lymphotoxin; RA, rheumatoid arthritis.
The K/BxN TCR transgenic mouse is recently developed model of inflammatory arthritis (5–9). A ILK/BxN animal spontaneously shows an autoimmune disease with arthritis (although not all of the clinical, histological, and immunological features of RA in human). The disorder is critically dependent on both T and B cells. Although the pathologic manifestations are joint-specific, the process is initiated, and then perpetuated, by dual T/B cell autoactivity to a ubiquitously expressed antigen, glucose-6-phosphate isomerase (6-P). Transfer of anti-6-P IgGs from arthritic K/BxN mice into healthy animals elicits arthritis within days, even when the recipients are devoid of lymphocytes. GPI-anti-GPI immune complexes are the link between the systemic T and B lymphocyte autoactivity and the ensuing joint-specific inflammatory arthralgia and destruction; the joint specificity is perhaps a reflection of the presence of GPI on the articular cavity surface (1). Initiation of the inflammatory effector phase requires both the complement network and Fc receptors (11). The relevance of the K/BxN model to human RA is supported by a recent report that serum from almost two thirds of RA patients contains anti-GPI Abs, absent from serum of normal individuals or of patients with lupus arthritis or Sjogren’s syndrome (12), although one recent data show less obvious a correlation (unpublished data). The observation of GPI and GPI-anti-GPI complexes on cartilage surfaces of human joint is also of interest (10).

Our early studies on K/BxN mice revealed augmented local synthesis of inflammatory cytokines, such as IL-6 and TNF-α, in arthritic joints (5). However, the functional relevance of these observations was not tested, other than a report that failed to demonstrate a required role for TNF in TNF-α, in arthritic joints (5). The role of inflamma tory cytokines in the early phase of the disease is critical. Interestingly, we find that the requirement for TNF is dependent on the disease and rather to the variance resistant to TNF/TNF blockade.

Here, we apply the K/BxN serum transfer system to a panel of mice deficient in one or more inflammatory cytokines or their receptors. A critical role for IL-1 is established, even with a strong, but not absolute, requirement for TNF. Interestingly, we find that the serum transferred has marked from individual to individual, as it does in human.

Materials and Methods

Mice. The knockout mice used for serum transfer were obtained from the Jackson Laboratory, brought to our animal facility at the NIAID Medical School animal facility at 4–5 wk of age, and used 1–3 wk later (in rare exceptions, the mice were used in our colony). These mice include the following: IL-6 (14) on a B6 background; IL-1β (15) on both B6 (16) and 129/F2 (16) backgrounds; TNF-α (17) on a B6 129/F2 background; IL-10 (18) on both the IL-10-/- and B6 129/F2 (18) backgrounds; TNF-α (19) on a B6 129/F2 background; IL-6 (16) on a B6 129/F2 background.

Results and Discussion

Kinetics of Inflammatory Cytokine Production. Transfer of K/BxN serum into normal recipients induces rapid and synchronous development of arthritis, the first signs of joint inflammation appearing within 24 h in fully susceptible strains (9). To begin exploring the induction of inflammatory cytokines in this model and their temporal relationship, we measured the expression of their mRNA by quantitative real-time PCR. C57B/6 mice were injected with 150–200 μl serum at days 0 and 2. A clinical index was evaluated over time, with 1 point for a paw with only mild swelling, redness or only a few digits affected. Ankle thickness was measured by a caliper (6), with ankle thickening being defined as the difference in ankle thickness from the day 0 measure.

Histology. Histological sections were collected and the knee and ankle joints were removed and fixed in 10% formal saline for 2 wk in 14% EDTA, followed by paraffin embedding (model Citadel 1000; Shandon). For each specimen, 24 m sagittal sections were cut, and every fifth section was stained with hematoxylin and eosin (H&E). Immunohistochemical staining was performed as described previously (6, 23).

Inflammation in K/BxN Arthritis

RNA Analysis. RNA was prepared from ankle tissue by a modification of the LiCl/urea technique (22), designed to avoid contamination of the joint RNA with bone marrow-derived material by leaving the bone intact. A fixed section of ankles (sections at the long bones of the lower leg and mid and in the metatarsal area), the tissue was washed of skin and superficial tendons. The joint was immersed in 1 ml RNA solubilization solution (6 M urea, 2% SDS). A total of tissue was homogenized and washed with a solution and then washed with the medium to release the cellular contents. After 10–15 min of incubation, the frozen tissue was removed, and an equal volume of concentrated LiCl solution (6 M LiCl, 6 M urea, and 10 mM sodium acetate, pH 5) was added to precipitate the RNA. DNA was synthesized from these RNA by MuLV reverse transcriptase (GIBCO BRL).

Cyclophilin was used as an endogenous control using a probe concentration of 200 and 400 nM for each primer in each reaction. The probe and primer sequences used are as follows: probe, 5′ CTGGGCGCCGCTCCTTT TAMRA 3′; forward primer, 5′ CACAGCCACTGCTGTTT 3′; and reverse primer, 5′ TGGCTTTGGAACCTTGGTCTGCAA 3′. The concentration of TNF and IL-6, the Tapm on a panel of mice deficient in one or more inflammatory cytokines was measured. The probe and primer sequences used are as follows: probe, 5′ TAMGACGCTGAGAAGTGTGTTCCATCCCTA 3′; forward primer, 5′ TGAAGACGCACACCCCA 3′; and reverse primer, 5′ AACGCCTTTCATCCTTCTTCT 3′. To determine the relative expression values, Cβ (cyclophilin), Cα (cytokine), and Cβ (cyclophilin) was used to derive an expression index (2–Cβ), which was then divided by the same index obtained with a reference sample pool of total human RNA. The probe and primer sequences used are as follows: probe, 5′ TAMGACGCTGAGAAGTGTGTTCCATCCCTA 3′; forward primer, 5′ TGAAGACGCACACCCCA 3′; and reverse primer, 5′ AACGCCTTTCATCCTTCTTCT 3′. To determine the relative expression values, Cβ (cyclophilin), Cα (cytokine), and Cβ (cyclophilin) was used to derive an expression index (2–Cβ), which was then divided by the same index obtained with a reference sample pool of total human RNA.
jected with a single dose of K/BxN serum, RNA was prepared at different times thereafter from ankle tissue (pooled from two individuals), and real-time PCR was performed to quantitate spliced TNFα, IL-1β, and IL-6 mRNA transcripts. A representative experiment is shown in Fig. 1.

The first signs of induction were detectable a few hours after serum injection, with a modest but detectable rise from the baseline for all mRNAs at 6 h. TNFα mRNA increased more substantially from 24 h onwards. IL-1 transcripts followed roughly the same pattern, but with a sharper induction at 48 h and far more extensive induction, reaching a 13,000-fold increase at 144 h. IL-6 showed a delay, with an increase at 72 h followed by a decline at 144 h that was reproducibly observed in several experiments. These results are consistent with an early appearance of inflammatory cytokine transcripts (from cell recruitment, or from true induction of gene expression, or both), and a secondary, far more extensive induction. The induction of IL-1 appears significantly more extensive than that of TNFα.

No Role for IL-6. The induction of arthritis by K/BxN serum transfer does not require any contribution from T or B cells (6). Thus, one can readily evaluate the role of inflammatory cytokines purely on the effector phase of the disease, unencumbered by their influences on the immunological induction phase. Such complications may have clouded results from collagen-induced arthritis (CIA) and antigen-induced arthritis models, where the known pleiotropic effects of such cytokines on the structure or responsiveness of the immune system complicate data interpretation. The K/BxN serum transfer system is applicable to a number of mouse strains (9), allowing one to investigate the effects of diverse natural and engineered mutations. This strategy was applied here, focusing on the contributions of IL-1, IL-6, and members of the TNF family, by transferring K/BxN serum into homozygous knockout mice lacking particular cytokines or cytokine receptors.

Figure 1. Kinetics of inflammatory cytokine expression. Arthritis was induced by injection of K/BxN serum into naive C57Bl/6 mice, and RNA was prepared from ankle joint cavities at various points thereafter. mRNA encoding inflammatory cytokines were quantitated by real-time PCR using cyclophilin mRNA as an internal standard. The results are presented as relative expression of individual cytokine mRNAs standardized against a reference sample of total spleen RNA from a normal mouse. This is a representative experiment (of three), with two mice pooled for each point.

97 J et al.

The induction of arthritis by K/BxN serum transfer does not require any contribution from T or B cells (6). Thus, one can readily evaluate the role of inflammatory cytokines purely on the effector phase of the disease, unencumbered by their influences on the immunological induction phase. Such complications may have clouded results from collagen-induced arthritis (CIA) and antigen-induced arthritis models, where the known pleiotropic effects of such cytokines on the structure or responsiveness of the immune system complicate data interpretation. The K/BxN serum transfer system is applicable to different mouse strains (9), allowing one to investigate the effects of diverse natural and engineered mutations. This strategy was applied here, focusing on the contributions of IL-1, IL-6, and members of the TNF family, by transferring K/BxN serum into homozygous knockout mice lacking particular cytokines or cytokine receptors. mRNA of matched genetic composition, bred in the same colony, were used as controls. In most cases, we preferred not to rely on injected cytokine inhibitors, such as anti-cytokine antibodies or soluble receptor molecules because negative results with such reagents can be difficult to interpret (sufficient dose or stability of the compound? completeness of the blockade?). This is particularly an issue in a context as aggressive as that of K/BxN arthritis.

We first investigated the importance of IL-6, a pleiotropic cytokine expressed by a variety of cell types during inflammatory processes (24). IL-6 has complex pro- and anti-inflammation influences, with both local and systemic effects. For example, it promotes in m responses and plasm cell and macrophage differentiation (25), but also induces acute phase proteins, IL-1 receptor antagonist (26), and metalloproteinase inhibitors (27). Its role is variable in different inflammatory models (28). There have been conflicting reports of the requirement for IL-6 in animal models of arthritis, some investigators describe reduced disease in IL-6-deficient mice or after antibody blockade of its receptor (29, 30), whereas others report no such effect (31).

IL-6-deficient mice on the C57Bl/6 background (14) were transferred with serum from arthritic K/BxN mice, and arthritis development was monitored as described previously (6). The representative experiment in Fig. 2A demonstrated a very similar arthritis course in IL-6-deficient and control mice. The initial onset of symptoms was the same, all distal joints were affected, and with a comparable degree of inflammation (measured as ankle thickness). These observations were confirmed by results from three individual experiments tabulated in Fig. 2B. Histological examination of the ankle joints revealed the image of synovitis and joint infiltration typical of K/BxN mice (synovial thickening and infiltration, presence of neutrophils in the articular cavity, pannus from ation, and cartilage destruction; Fig. 2C; unpublished data). Furthermore, cartilage damage and proteoglycan loss were evident on toluidine blue-stained ankle sections from serum-injected mice at comparable levels for IL-6-deficient and control mice (unpublished data).

These data are in agreement with those of van den Berg and colleagues, who found little role for IL-6 in joint inflammation in CIA or zymosan-induced arthritis (31). They contrast with other reports showing an effect of IL-6 blockade in the CIA model (29, 30). The explanation for these discrepancies may lie in the positive impact of IL-6 on the immunological induction phase of the CIA, modulation of neutral in m responses was made to the collagen-II antigen in the absence of IL-6 function (29, 30). Together, then, the data are consistent with the notion that IL-6 does not play a major role in the inflammatory effector phase of arthritis.

An Essential Role for IL-1. Although attempts at blocking the IL-1 pathway in RA patients in therapeutic trials have not met with as much success as those interfering with the activity of TNFα, there is substantial body of evidence implicating this inflammatory cytokine in several
classic murine arthritis models, whether autoimmune in nature or induced by local microbial particles (32–36); similarly, high levels of IL-1 transcripts have been detected in RA synovium (4, 37).

We tested the susceptibility to serum-transferred arthritis of the IL-1R knockout strain (15), in which neither IL-1 nor IL-1R-mediated signals are possible. After K/BxN serum transfer, essentially no clinical signs of disease were observed in the IL-1R-deficient mice, except for a limited swelling of the digits and a slight flattening in the ankle-thickness curve (Fig. 3). To guard against possible influences of genetic background variability, we repeated the initial experiments performed in B6 129F2 mice in IL-1R–deficient and control mice (matched for gender/age and genetic background) (our standard fully susceptible background; reference 11). Mated wild-type controls responded as usual. Histologically, no signs of joint inflammation were apparent in the four mice analyzed. CARTilage destruction and bone erosion were absent.

These clear-cut results indicate that, in this serum-transferred model mediated by arthritogenic IgG, IL-1 plays a central role, critically required for disease progression. We have not been able to reproduce this effect by treatment with blocking anti-IL-1R mAb (unpublished data), likely because of the known difficulty to achieve complete blockade of IL-1 action with biologic inhibitors (for review see reference 4).

The central importance of IL-1 in the K/BxN model is reminiscent of its requirement in CIA and other murine arthritis models (32, 33, 35). It is also consistent with the finding that in a particular expression of IL-1β alone is sufficient to induce full-blown arthritis (38).

TNF Family Influences. Members of the TNF family have received a great deal of attention in the context of inflammatory arthritis. This has ranged from the initial demonstration of TNF− expression in arthritic synovium, to establishing the efficacy of TNF−/TNF receptor–blocking agents in animal models, to the successes of such reagents in therapeutic intervention in human RA (1, 4, 39–42). Absent expression of TNF− is also sufficient to induce arthritis in transgenic animals (43). These results evoked models of arthritogenesis in which TNF− plays a central and indispensable role (for review see 1).

We tested the efficacy of K/BxN serum transfer in animals carrying knockout mutations of the genes encoding TNF− or its close homologue, lymphotoxin (LT)− (17–21). TNF− and LT− mediate their pleiotropic effects by binding to one of two known receptors, TNFR1 (p55) and TNFR2 (p75).

We also investigated the effect of knockout mutations of the genes encoding either or both of these molecules. The data, summarized in Table 1, allow several conclusions. First, and most simply, LT− seemed not to be required for the development of K/BxN serum-transferred arthritis. LT− deficient mice responded normally on all counts, in the kinetics and intensity of inflammation and in the appearance of histological lesions (proliferative synovitis, infiltration of the joint cavity by neutrophils, and forma tive of a destructive pannus).

Second, the absence of TNF− had a marked effect in particular. Mice lacking TNF− developed no disease whatever upon transfer of K/BxN serum, either clinically or histologically (Table 1). However, a number of such animals did develop joint inflammation, overall in 970

---

**Figure 2.** No requirement for IL-6 in arthritis induced by K/BxN serum transfer. IL-6-deficient and control mice (matched for gender/age and genetic background) were injected with 150 μl serum from arthritic K/BxN animals on days 0 and 2. A phenotype was evaluated by measuring clinical index and ankle thickening. Mice and methods. B. Data from a representative experiment, with each curve representing an individual mouse. B) Tabulation of the results for 10 knockout mice and age/gender-matched controls on either the standard B6 129F2 background or on an inbred B6 background. Scoring as described for Fig. 2; the star denotes a transient inflammatory reaction in the digits of one mouse.

**Figure 3.** Essential role of IL-1. IL-1R−deficient and control mice (matched for gender/age and genetic background) were injected with 150 μl serum from arthritic K/BxN animals on days 0 and 2. Arthritis was evaluated by measuring clinical index and ankle thickening as in Fig. 2. A) Data from a representative experiment in B6 recipients, with each curve representing an individual mouse. B) Tabulation of the results for eight knockout mice and age/gender-matched controls on the standard B6 129F2 background or on an inbred B6 background. Scoring as described for Fig. 2; the star denotes a transient inflammatory reaction in the digits of one mouse.
23 examined over the course of this study. This finding is illustrated for representative cohorts in Fig. 4. The presence of responder TNF−/− mice was not restricted to one or two experimental groups, but was observed in a number of independent experiments. In contrast, a certain degree of clustering was observed, some experimental groups showing a high incidence of arthritis development (see below). When disease did develop, the time of onset was quite variable, usually delayed by several days relative to wild-type controls, and the degree of inflammation always remained below the maximum attainable. Histological analysis also revealed significant signs of inflammation in those mice with clinically detectable arthritis.

Third, joint inflammation developed normally in both the TNFR1−/− and TNFR2−/− deficient mice, as well as in TNFR1/TNFR2 double−deficient animals (Table I; the genotypes of the mice were reconfirmed at the end of the experiment). Clinical and histological parameters were essentially indistinguishable from normal controls. This observation was quite unexpected, as TNFR1 and TNFR2 are the only known receptors for TNF−, with no reported indication of another possible receptor in spite of the broad attention that TNF− has received (44). As both the cytokine and cytokine receptor mutations were on a susceptible (B6 129) F2 background, one would have expected that they have the same phenotype in both deficient strains.

These conflicting results prompted us to question the effect of the TNF− mutation; was the poor responsiveness in TNF−/− deficient mice truly due to the absence of the cytokine, or instead to some independent factor (a linked gene effect, quite plausible given the genomic localization of the TNF locus; an independent mutation; protective genes segregating by chance, etc.)? If the former were true, it should be possible to complement the deficiency by TNF− replacement, e.g., by triggering TNF FR1 with an agonistic mAb. To test this prediction, we injected cohorts of TNF−/− deficient mice with K/BxN serum, selected those mice that remained free of arthritis after 7 d, and administered the agonistic anti-TNF FR 1 Ab 55R−593 (45). As shown in Fig. 5, the Ab had a marked effect, provoking arthritis in all the TNF−/−− deficient mice that had previously received K/BxN serum. No arthritis was observed when 55R−593 was injected without serum pretreatment (unpublished data). Several control Abs were used in parallel to rule out trivial explanations for this observation: an isotype-matched control Ab, anti-TNF FR 1 mAbs with blocking or antagonist activity (55R−170, 55R−286). None of these reagents induced arthritis (Fig. 5 B), at least not beyond the minority of TNF−/− deficient mice one might expect to eventually progress spontaneously to arthritis on the basis of the results presented in Fig. 4. Thus, results from these experiments confirm that TNF−/− deficiency indeed plays the element missing in TNF−/− deficient mice that is required for robust development of arthritis.

Table I. Arthritis Incidence in Mice Deficient in TNF and TNFR Families

<table>
<thead>
<tr>
<th>Strain</th>
<th>Arthritis Days of onset</th>
<th>Max CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNFR1/B6</td>
<td>8/8</td>
<td>4,2,2,1,1,2,2</td>
</tr>
<tr>
<td>TNFR2/B6</td>
<td>8/8</td>
<td>4,2,2,1,1,2,2</td>
</tr>
<tr>
<td>TNFR1/2/B6x129F2</td>
<td>6/6</td>
<td>2,2,1,4,2,2</td>
</tr>
<tr>
<td>Lt/B6x129F2</td>
<td>8/8</td>
<td>2,2,2,2,2,1,4,2</td>
</tr>
<tr>
<td>TNF/B6x129F2</td>
<td>4/14</td>
<td>2,2,2,3,5,4,2,3,3</td>
</tr>
<tr>
<td>TNF/B6x129F2</td>
<td>9/9</td>
<td>2,2,2,3,5,4,2,3,3</td>
</tr>
</tbody>
</table>

Figure 4. Variability of arthritis in TNF−/− deficient mice. TNF−/− deficient and control mice were injected with 150 μl serum from arthritic K/BxN animals on days 0 and 2. Arthritis was assessed by measuring ankle thickening as in Fig. 2. The data are pooled from six different experiments. All mice originated from the Jackson Laboratory.
Further experiments were performed to address the cause of the variable effect of the TNF- deficiency. It could be explained by genetic, epigenetic, or environmental variation controlling the activity of TNF- independent pathways; stochastic threshold effects could also be involved, as in the absence of local inflammation, only seldom reached in the absence of TNF- . As the knockout mice were crossed on a m. inbred F2 background, we reasoned that m. idiosyncratic at other loci, able to complement or nullify TNF- deficiency, might segregate randomly in the F2 knockout mice. To test this hypothesis, several crosses were set up between combinations of resistant or susceptible TNF- deficient m. mice. Should alleles at independent loci be segregating, these should be heritable traits in the progeny. As shown in Fig. 6 A, this was not the case. A cross between two resistant m. mice yielded a dominant proportion of responder m. mice; the transduction of a recessive susceptibility allele in this family would be very unlikely to yield such a pattern (P < 0.003). Thus, the variability does not stem from Mendelian genetic elements. Epigenetic variation could perhaps account for these results. However, we observed a clear correlation between the origin and life history of the m. mice and their responses to K/BxN serum (Fig. 6 B). Those m. mice bred at the Jackson Laboratory and shipped to Boston 7–15 d before challenge showed m. mice with a resistant phenotype, whereas those bred in Boston and tested there were mainly susceptible (P < 0.003). In both cases, barrier facilities have SPF status, free of major pathogenic m. mouse pathogens, but m. minor bacterial flora varies. Thus, the segregation of responses is one consistent with an environmental explanation than with an epigenetic one.

Together, these experiments point to a distinct involvement of TNF- in Ab-induced arthritis, but one that is not absolutely essential. This conclusion differs from that reached by Kyburz et al. (13), who found no effect of anti-TNF- therapy in arthritis development in straight K/BxN transgenic m. mice. We have also made similar observations, injecting several different anti-TNF- reagents into young K/BxN m. mice (unpublished data). However, we interpret these negative results with caution because of the very aggressive nature of the disease that develops in the transgenic m. mice and uncertainties concerning the efficiency of Ab-mediated blockade. On the other hand, the present results do concur with reports of robust development of CIA in TNF- deficient m. mice (46). Although it is conceivable that the cytokine network adapts so that TNF- is not the indispensable cytokine for the development of Ab-induced arthritis. The significant m. mouse-to-m. mouse variability we observed with TNF- deficient m. mice is, in a sense, reminiscent of the variability in the response of RA patients to TNF- / TNF FR blockade (1). The results of Fig. 6 make it perhaps more plausible that environmental effects are at play, the degree of TNF- involvement being dependent on the general inflammatory state of the individual. It should be worthwhile trying to pinpoint what these influences might be, in both m. mice and humans, and the present system provides a handle.

There are several potential interpretations for the strong arthritis that develops in TNF-/- deficient m. mice. The most straightforward is that other receptors can compensate and mediate TNF- signals. Although the existence of such a receptor has not been reported to date, the benefit of the TNF-/- family makes it quite possible that other receptors will be found to bind TNF- . Whether these are indeed the primary receptors mediating arthritis, or whether they only come into play when the primary TNF FR 2 receptors are absent, will need to be explored. Alternatively, one might suppose that TNF- independent arthritis pathways are particularly active when TNF FR 2 are missing, perhaps by overcoming downstream signal transduction adap-

Figure 5. Triggering the TNF receptor complement TNF deficiency. TNF-/- deficient m. mice were injected with 150 l of K/BxN serum on days 0 and 2. Arthritis was scored using a 0–3 grading system, with arthritis present in the first 10 d after serum transfer. In both m. mice and humans, CIA is a disease of clear arthritis [grade 1] in the first 10 d after serum transfer. The data are pooled from four different experiments. All m. mice originated from the Jackson Laboratory.

Figure 6. Environmental, not genetic, influences on TNF-/- deficient m. mice. A) TNF-/- m. mice from the Jackson Laboratory were injected with K/BxN serum, and arthritis assessed as described above. The data are pooled from four different experiments. All m. mice originated from the Jackson Laboratory. B) The origin of mice.
tors. For example, the absence of TNFR1 might free TRADD, FADD, or TRAF molecules for more efficient interaction with other receptors.

Bone Destruction and Formation. There is some debate about the role of inflammatory cytokines in promoting focal bone erosion in the course of arthritic diseases. Osteoclasts are essential to the process, and essentially no focal destruction of the bone occurs in their absence. Resistance to bone erosion was previously demonstrated in mice deficient in the TNF family member receptor activator of NFκB ligand (RANKL) that had received K/BxN serum, as in the CIA model after blockade of RANKL by osteoprotegerin treatment (23, 47). This finding is consistent with the fact that RANK/RANKL axis is required for the generation of osteoclasts and also plays a role in their activation (for review see reference 48). In contrast, it is also possible that other inflammatory cytokines play a role. IL-1 can activate osteoclasts, and promotes bone resorption in vitro (49, 50). TNF promotes osteoclast differentiation in the presence of RANKL (51, 52), and there are indications that TNF/TNF receptor blockade can retard bone destruction in RA patients, even when the effect on the inflammatory component is limited (53). Thus, we asked whether bone destruction could be seen in the absence of these cytokines. As described previously, obvious instances of focal bone destruction were seen in normal mice injected with K/BxN serum; similar images were also observed in LT-deficient mice (Fig. 7, A and B). For TNF-, we focused in particular on those mice that showed significant joint inflammation. In these instances, clear evidence of focal bone destruction was also observed (Fig. 7 C). Although impossible to truly quantitate, given the variability of inflammation in the TNF-deficient animals, the extent of the erosive lesions in the absence of TNF was largely on par with the extent of inflammation.

We could not draw any conclusion on the role of IL-1 in bone destruction, as the upstream inflammatory phase did not develop in its absence. However, our results are not consistent with the view that TNF plays an obligate role in promoting bone destruction; synovitis and joint inflammation could still lead to extensive destruction in its absence.

Synthesis: Intersection of IL-1 and TNF Pathways. There has been quite some debate as to the relative roles and importance of IL-1 and TNF in arthritogenesis. In animal models where the function of these cytokines has been tested, their in postance varies somewhat with the disease-eliciting agent, although IL-1 may play a dominant role in the cartilage and bone destruction that ultimately ensues (for review see reference 4). For Ab-mediated arthritis that the K/BxN disease may typify, our results point to a more crucial function for IL-1. These roles, and the slightly different kinetics of induction of cytokine transcription in the joint during arthritis initiation, are consistent with a model in which the point of action of TNF- would be upstream of that of IL-1 (1). TNF-independent pathways, perhaps relying on other members of the TNF family, may also trigger IL-1 independently. This view is consistent with the in postance of TNF- in promoting IL-1 production by synovocytes from RA patients (54), or with the fact that IL-1 blockade prevents the arthritis induced by transgene-encoded TNF- in mice (55). It should also be pointed out that the experiments shown in Fig. 1 only detect transcriptionally induced TNF- production. However, it is likely that even earlier release of TNF- occurs in the first minutes or hours of the disease, released from intracellular stores of synoviocytes or mast cells upon triggering by C5a or FcRIII. These molecules constitute two essential links between the anti-GPI Abs and the inflammatory manifestations of K/BxN arthritis (11), and both pathways are known to precipitate rapid TNF- release.

The relevance of the Ab-mediated arthritis model that K/BxN mice present to human arthritic diseases had been questioned, in part, because it does not fit well with the paradigm in which autoreactive T cells within the joint provoke local TNF- release, a model bolstered by the...
successes of anti-TNF therapy. The present results show that arthritis induced by Ab complexes in the joint also end up with the production of TNF- and IL-1, and is highly dependent on these cytokines.

We would like to thank D.M. R. Schaefer for the generous gift of mAbs, and J. Herveaux, S. Johnson, and Q.M. Pham for excellently managing the KRN colony.

This work was supported by grants from the Association pour la Recherche contre la Polyarthrite and the National Institutes of Health (IR 01 AR/AI46580-01) to D.M. Athias and C. Benoist, and an Arthritis Foundation Biomedical Science grant to E. Gravallese. K.O. hunu received a fellowship from the Uehara Memorial Foundation and A. Pettijon supported by the National Health and Medical Research Council of Australia, and by the Arthritis Foundation.

Submitted: 19 March 2002
Revised: 25 April 2002
Accepted: 14 May 2002

References


